US4362567A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tissue adhesive
Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1980-02-04
•
Granted: 1982-12-07
•
Expires: 2000-02-04
Abstract
Abstract A tissue adhesive on the basis of human or animal protein contains factor XIII and at least 33% by weight of fibrinogen, has a ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen, of at least 80, contains fibrinogen and albumin in the total protein at a ratio of 33 to 90:5 to 40, contains plasminogen-activator-inhibitor or plasmin inhibitor in an amount of 250 to 25,000 KIU per g of fibrinogen and has been lyophilized.
Inventors
- 👤 Otto Schwarz
- 👤 Yendra Linnau
- 👤 Franz Loblich
- 👤 Thomas Seelich
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:07
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/14; A61K35/16; A61K38/00; A61K38/005; A61L; A61L24/00; A61L24/04; A61L24/10; A61L24/106; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
69 words
A lyophilized tissue adhesive of mammalian protein origin which comprises fibrinogen, albumin, factor XIII, cold-insoluble globulin and plasminogen-activator inhibitor or plasmin inhibitor wherein the fibrinogen is present in at least 33% by weight, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen is at least 80; and fibrinogen and albumin are present in a ratio of 33 to 90:5 to 40.
Claim 2
Dependent Claim
69 words
A lyophilized tissue adhesive of mammalian protein origin which comprises fibrinogen, albumin, factor XIII, cold-insoluble globulin and plasminogen-activator inhibitor or plasmin inhibitor wherein the fibrinogen is present in at least 33% by weight, the ratio of factor XIII to fibrinogen, expressed in units of factor XIII per gram of fibrinogen is at least 80; and fibrinogen and albumin are present in a ratio of 33 to 90:5 to 40.
Claim 3
Dependent Claim
15 words
A tissue adhesive as described in claim 1 wherein the plasminogen-activator-inhibitor or plasmin-inhibitor is aprotinin.
Claim 4
Dependent Claim
32 words
A tissue adhesive as described in claim 1 wherein the plasminogen-activator-inhibitor or plasmin inhibitor is present in an amount which is equivalent to 250 to 25,000 KIU aprotinin per gram of fibrinogen.
Claim 5
Dependent Claim
24 words
A tissue adhesive as described in claim 1 wherein the adhesive also contains material selected from the group consisting of glycine, glucose and sucrose.
Claim 6
Dependent Claim
22 words
A tissue adhesive as described in claim 1 wherein the adhesive also contains 0.2 to 200 IU heparin per gram of fibrinogen.
Claim 7
Dependent Claim
30 words
A tissue adhesive as described in claim 1 wherein the ratio of fibrinogen to albumin to cold-insoluble globulin in the total protein is 33 to 90:5 to 40:0.2 to 15.
Claim 8
Dependent Claim
16 words
A method of producing the tissue adhesive described in claim 1 which comprises the steps of:
Claim 9
Dependent Claim
44 words
treating a cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor and heparin to remove cold soluble plasma protein; 2. dissolving the purified precipitate; 3. adding human albumin to the resulting solution; and 4. lyophilizing the solution.
Claim 10
Dependent Claim
44 words
treating a cryoprecipitate with a buffer solution containing sodium citrate, sodium chloride, glycine, glucose, a plasminogen-activator-inhibitor or plasmin-inhibitor and heparin to remove cold soluble plasma protein; 2. dissolving the purified precipitate; 3. adding human albumin to the resulting solution; and 4. lyophilizing the solution.
Claim 11
Dependent Claim
17 words
A method as described in claim 7 wherein the cryoprecipitate is treated once with said buffer solution.
Claim 12
Dependent Claim
18 words
A method as described in claim 7 wherein the cryoprecipitate is treated several times with said buffer solution.
References Cited (Backward Citations)
CA448302A
Cited
US3523807A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-12-06 | 1986-06-07 | 1986-12-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-12-06 | 1990-06-07 | 1990-12-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-12-06 | 1994-06-07 | 1994-12-07 | $7700.00 | Window Closed / Lapsed |